PI3K/AKT inhibitors (such as BEZ235 and BKM120) (16), and inhibitors targeting the MAPK pathway (such as MEK and ERK inhibitors) (17), have shown potential in inhibiting bladder cancer cell growth in preclinical models. This evidence concerns the gene AKT1 and urinary bladder cancer.